| dc.description.abstract | Background: Diabetes mellitus is a disorder of sugar metabolism characterised by
hyperglycaemia that can be caused by abnormalities in insulin. Bitter melon is used
as an antidiabetic with the presence of biactive components such as cucurbitane and
flavonoids. One of the receptors that play a role in the treatment of diabetes is
PPAR-γ.
Purpose: To determine the secondary metabolites of bitter melon ethanol extract
against PPAR-γ receptors that have potential as antidiabetics in silico and in vivo.
Method: The stages in this study include LC-HRMS analysis, in silico testing
including prediction of biological activity using (PASS online), physicochemistry
(Drug design Lipinski), pharmacokinetics (SwissADME), toxicity (ProTox-II) and
molecular tethering with (Autodock Tools and Autodock Vina) and in vivo testing
by measuring fasting blood glucose levels using a glucometer and data analysis
using One way ANOVA statistics.
Result: In silico, selected chemical compounds from bitter melon that have
interactions with PPAR-γ receptors by looking at the low docking score and have
the same amino acid residues as the comparator are scopoletin, rutin, kaempferol-
3-O-arabinoside, 3-hydroxy-2-methylpiridine, karavilagenin e, scoparone,
apigenin, karaviloside iii, lycopene, and goyaglicoside b. In vivo, the ethanol
extract of bitter melon has antidiabetic activity by reducing blood glucose levels in
zebrafish. In vivo, bitter melon ethanol extract has antidiabetic activity by reducing
blood glucose levels of zebrafish best at a dose of 400 mg.
Conclusion: From the results of this study, it is known that bitter melon ethanol
extract has antidiabetic activity as evidenced in silico and in vivo. | en_US |
